COVID-19: Implications for People with Chagas Disease

Area of Science:

• Infectious Diseases
• Tropical Medicine
• Cardiology

Background:

• The COVID-19 pandemic disproportionately affects vulnerable populations, including those with neglected tropical diseases like Chagas disease (CD).
• Chagas disease, caused by Trypanosoma cruzi, can lead to severe cardiac and gastrointestinal complications, potentially increasing susceptibility to SARS-CoV-2.
• Over one million individuals globally have chronic Chagas cardiomyopathy, requiring specific attention during the COVID-19 pandemic.

Purpose of the Study:

• To assess the implications of coinfection with SARS-CoV-2 and Trypanosoma cruzi.
• To provide preliminary guidance for the testing, treatment, and management of patients with both Chagas disease and COVID-19.
• To highlight emerging healthcare access challenges and future research needs related to this coinfection.

Main Methods:

• Review of existing literature and evidence on SARS-CoV-2 and Trypanosoma cruzi coinfection.
• Development of preliminary clinical guidance based on current knowledge.
• Identification of gaps in research and healthcare provision.

Main Results:

• Coinfection with SARS-CoV-2 and Trypanosoma cruzi presents unique challenges, particularly for patients with Chagas cardiomyopathy.
• Limited evidence exists regarding the specific impacts of this coinfection.
• Preliminary guidance for patient management has been developed.

Conclusions:

• Urgent consideration is needed for patients with Chagas disease, especially those with cardiac involvement, in the context of the COVID-19 pandemic.
• Addressing healthcare access challenges is crucial for effective management.
• Further research is essential to better understand and manage SARS-CoV-2 and Trypanosoma cruzi coinfection.